Research programme: Eg5 antisense oligonucleotides - Isis Pharmaceuticals
Latest Information Update: 11 Feb 2011
At a glance
- Originator Isis Pharmaceuticals
- Mechanism of Action KIF11 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 01 May 2006 Preclinical trials in Cancer in USA (unspecified route)